南京地区34家医院2010-2012年双膦酸盐类药物应用分析

目的:了解双膦酸盐类药物的使用状况及趋势。方法:采用世界卫生组织推荐的限定日剂量为指标的分析方法,对南京地区34家医院2010-2012年的双膦酸盐类药物的销售金额、用药频度(DDDs)和日均费用(DDC)等进行统计、分析。结果:双膦酸盐类药物销售金额和DDDs逐年增加,销售金额平均增幅达25.5%,DDDs以年均14%的速度增长,DDC处于稳中略降的态势。双膦酸盐氯屈膦酸由于口服方便、价格便宜,市场占有率依然较高,2012年销售金额占10.65%。临床安全性和疗效方面更佳的第三代双膦酸盐占据了主要市场,以唑来膦酸(2012年销售金额占63.81%)和阿仑膦酸钠(2012年销售金额占12.59%)为主。结论:双膦酸盐类药物在骨吸收相关性疾病中的应用逐渐受到重视,第二代和第三代双膦酸盐已经占据了主要市场。

Analysis of the Utilization of Bisphosphonates Drugs in 34 Hospitals from Nanjing Area during 2010--2012

OBJECTIVE： To investigate the utilization and trend of bisphosphonates drugs. METHODS： Using.defined daily dose （DDD） index recommended by WHO, the utilization of bisphosphonates drugs in 34 hospitals from Nanjing area during 2010--2012 were analyzed statistically in terms of consumption sum, DDDs and DDC. RESULTS： Annual consumption sum and DDDs of bisphosphonates drugs increased by 25.5 % and 14% respectively, while DDC kept slight decrease yearly. Bisphosphonate elodronate obtained high market share （more than 10.65% in 2012） since convenient oral and cheap cost; contribute to sally and better effect, the third-generation bisphosphonate occupied the main market, mainly including zoledronic acid （market share of 63.81% ,2012） and alendronate （market share of 12.59%, 2012）. CONCLUSIONS： Bisphosphonates drugs have been gradually appreiated in the treatment of bone resorption and associated diseases. The second-and third-generation bisphosphonates have occupied the main market share.